Veru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz Buys 95,279 Shares

Veru Inc. (NASDAQ:VERU - Get Free Report) Director Michael L. Rankowitz acquired 95,279 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $0.55 per share, for a total transaction of $52,403.45. Following the acquisition, the director now owns 195,279 shares in the company, valued at approximately $107,403.45. The trade was a 95.28 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Veru Stock Performance

Veru stock traded down $0.02 during mid-day trading on Friday, reaching $0.57. 2,034,970 shares of the company were exchanged, compared to its average volume of 4,901,708. Veru Inc. has a twelve month low of $0.47 and a twelve month high of $1.92. The firm's 50-day simple moving average is $0.70 and its two-hundred day simple moving average is $0.76. The firm has a market cap of $83.83 million, a PE ratio of -2.20 and a beta of -0.54.

Veru (NASDAQ:VERU - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, equities research analysts anticipate that Veru Inc. will post -0.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VERU shares. HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Veru in a report on Thursday, January 2nd. Oppenheimer reissued an "outperform" rating and issued a $5.00 target price on shares of Veru in a research report on Tuesday, November 5th.

Institutional Trading of Veru

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its position in Veru by 309.2% during the 3rd quarter. Barclays PLC now owns 184,777 shares of the company's stock worth $142,000 after acquiring an additional 139,617 shares during the period. State Street Corp raised its position in Veru by 4.3% in the third quarter. State Street Corp now owns 2,072,065 shares of the company's stock worth $1,593,000 after acquiring an additional 84,483 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Veru by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company's stock worth $2,261,000 after purchasing an additional 131,720 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Veru by 142.8% during the 3rd quarter. Jane Street Group LLC now owns 96,454 shares of the company's stock worth $74,000 after purchasing an additional 56,736 shares during the period. Finally, Gladstone Institutional Advisory LLC increased its holdings in shares of Veru by 34.2% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company's stock valued at $44,000 after purchasing an additional 14,500 shares in the last quarter. 47.16% of the stock is owned by institutional investors and hedge funds.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.